Intravenous Immunoglobulin (IVIG) Market in Malaysia: Current Industry Growth, Share, Key Players and In-Depth Analysis

IVIG is considered the most effective treatment for hypogammaglobinemia, CIDP and immunodeficiency diseases.

PORTLAND, OREGON, USA, Aug. 22, 2022 / — The Malaysia Intravenous Immune Globulin (IVIG) market report provides market insights based on key parameters such as market size, sales , sales analysis and key drivers. The market size of the market is expected to grow massively over the forecast period (2019-2026). This report covers the impact of the latest COVID-19 on the market. The coronavirus (COVID-19) outbreak has affected every aspect of life around the world. This changed part of the market situation. The main objective of the research report is to provide users with an overview of the market. Initial and future assessments of rapidly changing market scenarios and their impact are covered in the report.

Download a free sample report:

The Malaysian IVIG market was worth $12,277,000 in 2015 and is expected to reach $18,649,000 by 2022, registering a CAGR of 6.1% from 2016 to 2022. The scope of IVIG has expanded as it is used to treat various neurological disorders. , hematological, dermatological and immunodeficiency, using improved clinical practices and state-of-the-art technologies.

The main key companies presented are:

Grifols SA,
Octapharma S.A.,
Green Cross Society,
Baxalta (County),
Bio Products Laboratory Ltd.,
Biotest SA,
CSL Behring,
Omrix Biopharmaceuticals Ltd.,
Bayer Health and
Baxter International Inc.

Key findings from IVIG market in Malaysia:

o Hypogammaglobulinemia represented the largest revenue in 2015 due to the lack of effective replacement therapy and early adoption of IVIG

o Myasthenia Gravis is expected to grow at the fastest CARG of 9.1% over the forecast period.

o Intravenous mode of administration was the most revenue-generating segment in 2015 and is expected to continue this trend during the forecast period.

o The 10% concentration held the highest market share in 2015. This trend is expected to continue throughout the forecast period.

Find out before you buy:

IVIG products have attracted considerable attention in recent years due to their high efficacy in the treatment of immune diseases. The prevalence of various antibody deficiency disorders such as common variable immunodeficiency (CVID), specific antibody deficiency and hypogammaglobulinemia, increased indications for IVIG, improved production and purification processes, Increased awareness of antibody deficiency and rare immune disorders among the patient population is driving the growth of the IVIG market.

However, the high costs associated with IVIG treatment; shortage of IVIG; and side effects of IVIG treatment such as headache, migraine, fever, nausea or vomiting, and cough are hampering market growth. IVIG products are widely used for the treatment of immunodeficiency disease, ITP, chronic lymphocytic leukemia (CLL), Kawasaki disease and others. Malaysia’s untapped potential as an emerging market and the development of cost-effective therapies through large-scale production provide opportunities for market players in this region.

Hypogammaglobulinemia and CIDP held dominant market shares in 2015 due to large patient population and unavailability of effective alternatives to IVIG treatment. Based on product type, the market is segmented into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. Based on the concentration, it is classified into 5%, 10% and others. By method of administration it is divided into intravenous, subcutaneous and intramuscular mode of administration. The intravenous mode of administration segment generated the largest revenue in 2015 and is expected to continue this trend during the forecast period. The high bioavailability of immunoglobulins and the rapid absorption rate offered by the intravenous mode of administration are the factors that complement the growth of IVIG market by intravenous mode of administration.

More related trend reports:

Renal Denervation Market:

Austrian Flow Cytometry Market:

Syphilis Testing Market:

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global corporations as well as small and medium enterprises with unrivaled quality of “market research reports” and “Business Intelligence solutions”. AMR has a focused vision to provide business insights and advice to help its clients make strategic business decisions and achieve sustainable growth in their respective market areas. AMR offers its services in 11 industry sectors, including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverage, Energy & Power, semiconductors and electronics, automotive and transport, ICT and media, aerospace and defense and BFSI.

We maintain professional relationships with various companies which helps us to extract market data which helps us to generate accurate research data tables and confirm the utmost accuracy of our market predictions. Allied Market Research CEO Pawan Kumar helps inspire and encourage everyone associated with the company to maintain high quality data and help clients in every way possible to achieve success. All data presented in the reports we publish are drawn from primary interviews with senior managers of large companies in the relevant field. Our secondary data sourcing methodology includes extensive online and offline research and discussions with knowledgeable industry professionals and analysts.

David Correa
Allied Analytics LLP
write to us here
Visit us on social media:

Comments are closed.